@article{JTD17226,
author = {Jin-Tao Fu and Mohammad Sharif Popal and Hai-Bo Zhang and Wei Han and Qiu-Ming Hu and Xu Meng and Chun-Ye Ma},
title = {A meta-analysis of late outcomes of mitral valve repair in patients with rheumatic heart disease},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {11},
year = {2017},
keywords = {},
abstract = {Background: Rheumatic heart disease (RHD) is a predominant health concern in developing countries. The aim of this meta-analysis was to evaluate the outcomes of mitral valve (MV) repair in patients with RHD, and identify predictors that may postoperatively affect treatment outcome.
Methods: A meta-analysis of eligible studies assessing patients undergoing MV repair with RHD and reporting the outcomes of MV repair, including 30-day mortality and long-term follow-up survival, MV reoperation rate and postoperative adverse events. Relevant English articles were searched up to 1 March, 2017 in Web of Science, PubMed, Google Scholar, Cochrane Library, EmBase, Elsevier, and Science Direct. Selected studies should meet all inclusion criteria, and underwent data extraction.
Results: A total of ten studies with 2,770 patients met all inclusion criteria, and were selected for assessment. Pooled analysis showed that 30-day mortality in patients with rheumatic MV disease after MV repair surgery was 1.9%, 95% confidence interval (CI) (0.8–2.9%); long-term survival was 97.3%, 95% CI (95.9–98.6%), and a freedom from reoperation rate of 93.6%, 95% CI (91.4–95.9%) was obtained; freedom from adverse events was 97.5%, 95% CI (95.2–99.8%).
Conclusions: The outcome of rheumatic MV repair is outstanding in terms of low early mortality, high long-term survival and freedom from valve-related complications, which may be very common in patients after rheumatic MV replacement; meanwhile, MV reoperation rate after initial surgery is acceptable. Surgeons may try to repair MV in RHD when it is feasible},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/17226}
}